Zoetis Inc. (NYSE:ZTS) Shares Sold by Sentry Investment Management LLC

Sentry Investment Management LLC decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 1,851 shares of the company’s stock after selling 301 shares during the period. Sentry Investment Management LLC’s holdings in Zoetis were worth $302,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. AMF Tjanstepension AB increased its stake in shares of Zoetis by 23.4% during the 3rd quarter. AMF Tjanstepension AB now owns 105,376 shares of the company’s stock valued at $20,594,000 after acquiring an additional 20,001 shares during the last quarter. Howard Capital Management Group LLC increased its position in Zoetis by 0.8% during the third quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after purchasing an additional 883 shares during the last quarter. Arkadios Wealth Advisors raised its stake in Zoetis by 2.5% during the third quarter. Arkadios Wealth Advisors now owns 5,045 shares of the company’s stock worth $986,000 after purchasing an additional 121 shares during the period. Pallas Capital Advisors LLC boosted its holdings in shares of Zoetis by 6.0% in the 3rd quarter. Pallas Capital Advisors LLC now owns 7,934 shares of the company’s stock valued at $1,440,000 after purchasing an additional 451 shares during the last quarter. Finally, SFE Investment Counsel grew its stake in shares of Zoetis by 1.9% during the 3rd quarter. SFE Investment Counsel now owns 27,461 shares of the company’s stock valued at $5,365,000 after buying an additional 514 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS opened at $168.60 on Wednesday. The firm has a market cap of $75.50 billion, a price-to-earnings ratio of 30.82, a PEG ratio of 2.78 and a beta of 0.90. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The business’s 50 day moving average is $166.26 and its two-hundred day moving average is $177.66. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently weighed in on ZTS shares. Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. Barclays raised their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Piper Sandler decreased their target price on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a report on Monday, February 10th. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, Leerink Partnrs upgraded shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $215.40.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.